Moxham J, McAllen M
Clin Allergy. 1979 Jan;9(1):61-4. doi: 10.1111/j.1365-2222.1979.tb01523.x.
A controlled clinical trial comparing inhalation of disodium cromoglycate (DSCG) and of ICI 74,917 was carried out using a double-placebo technique in thirty-two patients with extrinsic asthma already shown to be reasonably responsive to DSCG. In view of the fact that ICI 74,917 is 300 times more potent than DSCG in inhibiting antigenic challenge in animals a better effect was anticipated from the new drug in the human asthmatic subject. Whilst this was not obtained, there appeared to be no lesser effect than that of DSCG.
在32例已证实对色甘酸二钠（DSCG）反应良好的外源性哮喘患者中，采用双盲安慰剂技术进行了一项比较吸入色甘酸二钠（DSCG）和ICI 74,917的对照临床试验。鉴于ICI 74,917在抑制动物抗原攻击方面比DSCG强300倍，预计这种新药在人类哮喘患者中会有更好的效果。虽然没有达到预期效果，但似乎效果并不比DSCG差。
